Skip to content
PeptideAI
In vitro onlyskin

Melanostatine-5

A competitive alpha-MSH blocker that shuts down the signal telling melanocytes to make pigment, rather than poisoning the tyrosinase enzyme downstream.

Also known as Nonapeptide-1, MSH antagonist peptide, Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2, Melanostatine 5, Melanostatine DM

In vitro only — Cell or tissue studies. A mechanism, not yet an effect in a living body.

The MC1R antagonism is well-characterised receptor pharmacology with published binding and functional numbers. Human skin efficacy data are supplier panels only, and penetration of a 1206 Da peptide to the melanocyte layer is the obvious open question.

How it works

Melanocytes make pigment when alpha-MSH binds melanocortin-1 receptor, raising cyclic AMP and inducing MITF, tyrosinase and the machinery for melanosome transfer to keratinocytes. Nonapeptide-1 is a selective MC1R antagonist with reported Ki around 40 nM that occupies the receptor without activating it, so the cAMP step never happens. In cell work it blocks alpha-MSH-induced cAMP with an IC50 near 2.5 nM and melanosome dispersion near 11 nM. Because it acts upstream of tyrosinase rather than on it, it is mechanistically complementary to hydroquinone, kojic acid or tranexamic acid rather than duplicative — and it does nothing about pigment already deposited in the skin.

Targets: Melanocortin-1 receptor (MC1R), Alpha-MSH signalling, cAMP / MITF pathway, Melanosome dispersion

Dosing

ProtocolDoseFrequencyRoute
Brightening serumMorning and night; the morning application is worthless without a broad-spectrum SPF over it.—twice dailytopical
  • · Trade solution used at 1-4% of the formula. From raw powder, 0.001-0.01% w/w — the receptor affinity is nanomolar, so very little peptide is needed.

Cycling

Continuous use during and after any pigment protocol; stopping lets melanogenesis resume immediately.

Work out your exact syringe units →

Pharmacology

Half-life
Not established. The D-Phe and D-Trp substitutions give it good resistance to peptidase degradation.
Onset
8-12 weeks minimum — you are preventing new pigment, so you have to wait for existing pigment to turn over with the epidermis.
Routes
topical
Molecule
Synthetic nonapeptide amide (D-amino acid substituted)
Sequence length
9 amino acids
Molecular weight
1206.5 Da

Handling

Diluent
Distilled or deionised water
Typical mix
20 or 50 mL
Vial sizes
50, 100, 200 mg
Lyophilised
Sealed, cool and dry; freezer for long-term.
Reconstituted
Refrigerated and preserved.

Mixing

Water soluble as the acetate salt.

Side effects

  • commonLoss of the tanning response in treated areas— That is the mechanism working, but it also means less physiological UV defence — sunscreen is not optional here.
  • rareIrritation

Do not use if

  • Use without daily broad-spectrum sunscreen — blocking MC1R suppresses the skin's own UV-protective tanning response.

Combining it

  • conflictmelitane — Direct pharmacological opposites at MC1R — one blocks it, the other activates it.
  • synergydecapeptide-12 — Receptor blockade upstream plus tyrosinase inhibition downstream.
  • synergytranexamic-acid — Different arms of the melasma cascade; commonly combined.

What to monitor

  • · Photographs under identical lighting, ideally with a cross-polarised filter which shows pigment far better than standard light.

Legal status

Cosmetic ingredient (INCI Nonapeptide-1) approved worldwide.

References

  • Wilczynski et al., MC1R antagonist peptide pharmacology (preclinical)
  • Lipotec Melanostatine 5 technical dossier (other)

Mechanism in depth

Melanogenesis runs on a single dominant switch and this peptide sits directly on it. UV exposure damages keratinocyte DNA, p53 is stabilised, p53 transactivates POMC, POMC is processed to alpha-MSH, and alpha-MSH is secreted onto neighbouring melanocytes. Alpha-MSH binds MC1R, a Gs-coupled receptor, which raises cAMP, activates PKA, phosphorylates CREB, and CREB drives transcription of MITF — the master melanocyte transcription factor. MITF then turns on tyrosinase, TYRP1, DCT, PMEL and the melanosome biogenesis and transport machinery, and separately drives melanocyte dendrite extension so pigment can be handed to more keratinocytes. Blocking MC1R with a competitive antagonist stops that cascade at step one, before any enzyme is transcribed. That is upstream of everything hydroquinone, kojic acid, arbutin and azelaic acid do, all of which act on tyrosinase or on melanosome transfer downstream. Which makes it genuinely complementary rather than duplicative. Two consequences follow, and both matter. First, it cannot do anything about pigment already made — melanin sitting in keratinocytes has to be shed with epidermal turnover, which is why the timeline is twelve weeks minimum. Second, and this is underappreciated, eumelanin is a real UV defence and MC1R signalling is the tanning response. Blocking it in skin that is getting sun exposure removes a protective mechanism. The sunscreen requirement here is not a legal disclaimer, it is a direct consequence of the mechanism.

What usually goes wrong

People run it for six weeks, see nothing and quit. That is the mechanism working exactly as designed — you are preventing new pigment while waiting for existing pigment to turn over, and epidermal turnover is four to six weeks per cycle, so you need at least two full cycles before anything looks different. The second problem is running it without sunscreen, which is not merely ineffective but arguably worse than doing nothing, because you have suppressed the tanning response in skin still receiving UV. The third is treating melasma as a pigment problem alone; melasma has vascular and inflammatory components and relapses hard, so a receptor antagonist alone will underperform. And the fourth is concentration: at nanomolar potency, the supplier level of 0.001-0.01% is already generous, and people formulating to 0.1% or 1% are burning money on an expensive peptide with no additional receptor to occupy.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
The D-phenylalanine and D-tryptophan substitutions confer substantial protease resistance, and the C-terminal amidation blocks carboxypeptidase attack. This is a deliberately stabilised peptide.
Elimination
No meaningful systemic exposure. Worth stating explicitly: this is a local MC1R antagonist and there is no systemic melanocortin effect, unlike injected melanocortin agonists.

Receptor targets

  • Melanocortin-1 receptor (MC1R) — Reported in supplier literature as Ki around 40 nM, with alpha-MSH-induced cAMP blocked at IC50 around 2.5 nM and melanosome dispersion at around 11 nM. I could not resolve these figures to a primary indexed publication.

    Competitive antagonism — occupies the receptor without activating Gs, so no cAMP rise, no CREB phosphorylation, no MITF induction.

  • cAMP / PKA / CREB / MITF axis (downstream) — Indirect

    Suppresses transcription of tyrosinase, TYRP1 and DCT, and reduces melanocyte dendricity.

What to expect, and when

Week 0-8: nothing visible. This is expected. Week 8-12: earliest change as the first epidermal cohorts turn over. Week 16-24: the point at which cumulative suppression looks like something. Maintenance is indefinite — stop and melanogenesis resumes immediately, because you removed a block rather than damaging a cell.

Stacking and comparisons

The best combination in the pigment category is receptor blockade upstream plus tyrosinase inhibition downstream — Melanostatine-5 with decapeptide-12, or with tranexamic acid, azelaic acid or a hydroquinone course. They hit different steps and the effects should compound rather than overlap. Tranexamic acid deserves particular mention because it works on the plasmin-driven inflammatory arm of melasma, which is a third independent route. Melitane is a direct pharmacological opponent — agonist versus antagonist at the same receptor — so never run both. The non-negotiable partner is broad-spectrum sunscreen with real UVA protection, because you are suppressing the skin's own photoprotective response while asking it to lose existing pigment.

Against hydroquinone, Melanostatine-5 is not cytotoxic to melanocytes and carries no ochronosis risk, but hydroquinone has decades of clinical data and a much larger effect size. The realistic role is maintenance after a hydroquinone course, not replacement of it. Against decapeptide-12, upstream versus downstream — decapeptide-12 has the published human melasma pilot and Melanostatine-5 has the better-characterised receptor pharmacology, and they combine. Against tranexamic acid, oral tranexamic acid has genuine randomised melasma data that no cosmetic peptide approaches. Against Melitane, direct opposites.

Rough cost

$15–$80/month. Raw nonapeptide-1 is expensive at roughly $80-200 per gram, but the use level is 0.001-0.01%, so a gram is effectively a lifetime supply. Finished brightening products $20-80 a month. Market observation, not a sourced pricing study.

Genuinely uncertain

  • The Ki of 40 nM and the IC50 figures of 2.5 nM and 11 nM are quoted throughout the cosmetic literature but I could not resolve them to a primary indexed publication in this session. Treat them as supplier figures.
  • No independent human trial of nonapeptide-1 on skin pigmentation exists.
  • Whether a 1207 Da peptide reaches the basal melanocyte layer in any meaningful quantity has never been measured.
  • The exact sequence Met-Pro-D-Phe-Arg-D-Trp-Phe-Lys-Pro-Val-NH2 is consistently reported for INCI Nonapeptide-1 but is unconfirmed against a primary source.
  • The molecular weight of 1206.5 Da in the Core record is unconfirmed against a primary source.
  • The long-term consequence of chronically suppressing MC1R signalling in sun-exposed skin is unstudied, and MC1R loss-of-function variants are an established melanoma risk factor — that is a mechanistic parallel worth thinking about, not a demonstrated risk of the cosmetic.

Papers